# **BMC Pharmacology**



Poster presentation

**Open Access** 

# Is kynurenine a novel and important vasodilator in human septic shock?

Yutang Wang\*<sup>1</sup>, Dechaboon Changsiri<sup>1</sup>, Gavin McKenzie<sup>2</sup>, Johannes-Peter Stasch<sup>3</sup>, Michael Hahn<sup>4</sup>, C Woolfe<sup>5</sup>, D Rajbhandari<sup>5</sup>, David S Celermajer<sup>5</sup> and Roland Stocker<sup>1</sup>

Address: <sup>1</sup>University of Sydney, Centre for Vascular Research, Bosch Institute, Sydney, Australia, <sup>2</sup>University of New South Wales, School of Medical Sciences, Sydney, Australia, <sup>3</sup>Bayer HealthCare, Institute of Cardiovascular Research, Wuppertal, Germany, <sup>4</sup>Bayer HealthCare, Medicinal Chemistry, Wuppertal, Germany and <sup>5</sup>Royal Prince Alfred Hospital, Sydney, Australia

Email: Yutang Wang\* - yutangwang@med.usyd.edu.au

from 4th International Conference of cGMP Generators, Effectors and Therapeutic Implications Regensburg, Germany. 19–21 June 2009

Published: 11 August 2009

BMC Pharmacology 2009, 9(Suppl 1):P70 doi:10.1186/1471-2210-9-S1-P70

This abstract is available from: http://www.biomedcentral.com/1471-2210/9/S1/P70

© 2009 Wang et al; licensee BioMed Central Ltd.

# **Background**

The enzyme indoleamine 2,3-dioxygenase (IDO) converts the amino acid tryptophan (Trp) to kynurenine (Kyn). IDO, which shares many functional similarities with iNOS [1], is also induced in sepsis [2]. Here, we investigated whether IDO plays a role in human septic shock and mouse endotoxemia akin to iNOS.

# Materials and methods

Patients (n = 16) with septic shock had IDO activity assessed (expressed as the ratio of Kyn to Trp) and the severity of their hypotension determined (expressed by inotrope requirement) during the course of illness. Normal and blood pressure-matched controls were also studied. Septic shock was induced in wild type and IDO-mice, and the effect of 1-methyl-tryptophan (1 MT, a competitive inhibitor of IDO) on blood pressure was determined. In animal studies, IDO expression and activity was assessed by IHC in resistance vessels and plasma Kyn, respectively. The direct vascular effect of Trp and Kyn was determined by vessel functional studies on mouse aortic rings.

### Results

Patients' inotrope requirement correlated with IDO activity (p < 0.001). IDO activity increased by up to 9-fold with

sepsis and was significantly higher than in the two control groups (Figure 1). In mice, endotoxemia led to hypotension, endothelial IDO expression in resistance vessels, and increased IDO activity. In both IDO-/- and the 1MT-pretreated animals, hypotension was attenuated significantly compared to wild-type controls (Figure 2). Similarly, administration of 1 MT to hypotensive mice restored blood pressure to normal. Kyn dose-dependently dilated mouse aortic rings, whereas Trp only dilated arteries from septic mice when IDO was expressed. Trp metabolites of




Figure I IDO activity in sepsis.

<sup>\*</sup> Corresponding author

#### Mice treated with 1MT were less hypotensive




Figure 2
Drop in blood pressure in mice.

the Kyn pathway other than Kyn were not vasoactive. Separate mechanistic studies indicated that Kyn relaxed blood vessels through activation of sGC and adenylate cyclase.

#### **Conclusion**

This study shows a significant correlation between IDO activity and hypotension in human septic shock, and that Kyn may act as a previously unrecognized and important vasodilator contributing to hypotension in sepsis. Inhibiting IDO in humans may provide a novel therapeutic target for the treatment of septic shock.

#### References

- Thomas SR, Stocker R: Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 1999, 4:199-220.
- Urade Y, Yoshida R, Kitamura H, Hayaishi O: Induction of indoleamine 2,3-dioxygenase in alveolar interstitial cells of mouse lung by bacterial lipopolysaccharide. J Biol Chem 1983, 258:6621-6627.

Publish with **Bio Med Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- ullet yours you keep the copyright

Submit your manuscript here: http://www.biomedcentral.com/info/publishing\_adv.asp

